In this online, self-learning activity:
Neutropenia, a decrease in the number of a type of white blood cell (WBC) in the body, is a common complication in patients undergoing myelosuppressive chemotherapy that can result in serious, life-threatening infections. Febrile neutropenia (FN), or neutropenia accompanied by a fever, poses an even greater risk to patients and the frequent treatment complication results in over 100,000 hospitalizations in the U.S. each year. Neutropenia can manifest up to twelve days following treatment with a chemotherapy agent and FN occurs in about eight per 1,000 patients receiving chemotherapy. Fever is defined as a single oral temperature of 38.3+ °C or 38.0+ °C over the course of an hour, with neutropenia defined as less than 500 neutrophils/mcL or less than 1000 with a predicted decline to less 500 over the following 48 hours. Development of FN may lead to hospitalization with costs estimated at approximately $15,000 per visit, and it may also complicate care by reducing chemotherapy relative dose intensity (RDI) and possibly compromise treatment efficacy and lower survival rates.
Oncologists and hematologists; physician assistants, nurse practitioners, and pharmacists who practice in oncology; and other HCPs with an interest in or who clinically encounter patients with FN or at risk of developing it.
Commercial Support Disclosure: This program is supported by educational grants from Coherus Biosciences and Mylan Inc., a Viatris company.
This activity is free of charge.
Release Date: September 20, 2022 -- Expiration Date: September 20, 2023
Faculty: Eric Tam, MD
Faculty introduction, disclosures
Chemotherapy-associated FN: defining the problem
Addressing the problem of FN associated with myelosuppressive chemotherapy
- Primary prophylaxis
- Secondary prophylaxis
- Therapeutic use in patients with FN and neutropenia without fever
- Roles of CSFs, biosimilar agents
- Dosing and timing, including long-acting agent considerations
- Cyclin-dependent kinases 4/6 inhibitors and their myeloprotective role in select diseases
- Treatment persistence
- Pandemic-related considerations
Summary, conclusions, and best practice recap
By the end of the session the participant will be able to:
This activity is not accredited.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.
Faculty Disclosure: Eric Tam, MD, Assistant Professor, Keck Medicine of University of Southern California, has received financial compensation from Maximus, Inc. for consulting work.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
Faculty will NOT discuss off-label uses.
All relevant financial relationships have been mitigated.
Commercial Support Disclosure: This program is supported by educational grants from Mylan Inc., a Viatris company, and Coherus Biosciences.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.